September 27, 2019
1 min read

Top stories in gastroenterology: generic Zantac recall, new keto diet insights and more

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

The top story in gastroenterology was Healio’s coverage of the fallout from reports that a possible human carcinogen was found in generic forms of Zantac.

Another popular story showed that a modified version of the keto diet could potentially reduce the risk for Alzheimer’s disease by impacting the gut microbiome. Read these stories and more gastroenterology news below.

Sandoz voluntarily recalls generic forms of Zantac

Sandoz has voluntarily recalled all generic forms of Zantac (ranitidine) in the United States after noting confirmed contamination with N-Nitrosodimethylamine (NDMA), a possible human carcinogen, above established FDA levels, according to a company press release. Read more.

Advanced neoplasia risk differs between diminutive, small adenoma at baseline

Patients with small adenomas — between 6 mm and 9 mm in size — at baseline colonoscopy have an elevated risk for advanced neoplasia at follow-up compared with patients who only have diminutive adenomas, according to study results. Read more.

Keto Mediterranean diet could modulate gut microbiome to reduce Alzheimer’s risk

Researchers found that a modified Mediterranean-ketogenic diet can impact the gut microbiome in a way that decreases risk for Alzheimer’s disease. Read more.

High - definition white-light endoscopy offers alternative for Lynch syndrome surveillance

Endoscopic surveillance for Lynch syndrome using high-definition white-light endoscopy was noninferior to surveillance using pancolonic chromoendoscopy, according to study results. Read more.

Microbiome may offer new biomarker for inflammatory bowel disease therapy response

Patients with inflammatory bowel disease who responded to certain therapies exhibited consistent changes in their gut microbiome, which could lead to new opportunities for precision medicine, according to results of a meta-analysis. Read more.